Key Developments: SCOLR Pharma Inc (SCLR.PK)
0.00USD
20 May 2013
$-0.00 (-40.00%)
$0.00
$0.00
$0.00
$0.00
40,000
84,958
$0.13
$0.00
Latest Key Developments (Source: Significant Developments)
SCOLR Pharma Inc Announces Termination Of CEO-Form 8-K
SCOLR Pharma Inc reported in its Form 8-K that the Company terminated its remaining employees, including its Chief Executive Officer (CEO), Stephen J. Turner, effective March 1, 2013. Full Article
SCOLR Pharma, Inc.'s Announces Positive Preliminary Results In Ondansetron Study
SCOLR Pharma, Inc announced that RedHill Biopharma Ltd., which has licensed the exclusive worldwide rights to use SCOLR's patented technology to develop an extended release version of the anti-emetic drug ondansetron (brand name Zofran), has received positive preliminary results in a pharmacokinetic study comparing its version of ondansetron with Zofran. RedHill said that, assuming the final clinical study report supports the preliminary findings, it will consider filing an application with the FDA for US marketing approval (New Drug Application – NDA) utilizing the clinical study as a pivotal clinical trial. RedHill announced that the initial analysis of the results indicates that the clinical study has met its objective of establishing bioequivalence to Zofran, the current approved reference listed drug. As previously announced, RedHill had submitted an Investigational New Drug application (IND) to the FDA and a Clinical Trial Application (CTA) to Health Canada seeking permission to compare the bioequivalence of its product, which it calls RHB-102, to Zofran, which is manufactured by GlaxoSmithKline. Zofran® is an anti-emetic drug (i.e. for prevention of nausea and vomiting) that is administered several times per day. RHB-102 is a once-daily controlled release tablet formulation of ondansetron, a serotonin 5-HT3 receptor antagonist. Full Article
SCOLR Pharma, Inc. Announces Resignation Of Executive Vice President And Chief Financial Officer-Form 8-K
SCOLR Pharma, Inc. reported in its Form 8-K that, on March 30, 2012, Richard M. Levy tendered his resignation as Executive Vice President and Chief Financial Officer of SCOLR Pharma, Inc. effective April 30, 2012. Full Article
SCOLR Pharma, Inc. Announces Initial Closing of Private Placement
SCOLR Pharma, Inc. announced that it has closed the sale of $1 million principal amount of its 8% Senior Secured Convertible Debentures due 2013 (Debentures) in an initial closing of its private offering of up to $1.75 million principal amount of Debentures. The Company may offer additional Debentures, up to the aggregate maximum of $1.75 million, until June 30, 2011, unless extended. The Debentures, together with accrued and unpaid interest thereon, are convertible at the option of the holders into shares of the Company's common stock at a conversion price equal to $0.05 per share of Common Stock. Beginning after the date that is six months from the issuance of the Debentures, the Company may cause mandatory conversion of the Debentures following the continuance for 30 consecutive days of certain conditions, including maintenance of a volume weighted average trading price on each day within such 30 day period of $0.25 per share of Common Stock. The Debentures bear interest at a rate of 8% per annum, compounded quarterly, and are secured by all the Company's assets. The Company intends to utilize the net proceeds of the offering for working capital and other general corporate purposes. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
